中国神经再生研究(英文版) ›› 2026, Vol. 21 ›› Issue (9): 4112-4121.doi: 10.4103/NRR.NRR-D-25-00495

• 综述:退行性病与再生 • 上一篇    下一篇

线粒体DNA稳态:神经退行性疾病的新型治疗靶点

  

  • 出版日期:2026-09-15 发布日期:2026-05-19
  • 基金资助:
    国家自然科学基金(82404601)

Mitochondrial DNA homeostasis: A novel therapeutic target for neurodegenerative diseases

Tingting Fu#, Xinyi Chen#, Shuting Zhang, Ying Fu, Ling Huang*, Wandi Xiong*   

  1. Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan Province, China
  • Online:2026-09-15 Published:2026-05-19
  • Contact: Wandi Xiong, PhD, xiongwandi@hainanu.edu.cn; Ling Huang, PhD, linghuang@hainanu.edu.cn.
  • Supported by:
    This work was supported by the National Natural Science Foundation of China, No. 82404601 (to WX).

摘要:

线粒体基因组稳态对氧化磷酸化系统功能及细胞稳态至关重要。线粒体DNA(mtDNA)由于缺乏组蛋白外壳,特别容易受到与衰老相关的氧化应激的影响。紊乱的线粒体DNA可能在衰老过程和神经退行性疾病中导致功能衰退,进而引发额外的线粒体DNA损伤,形成恶性循环。目前,紊乱的线粒体DNA如何参与病理性衰老和神经退行性疾病的病因尚不明确。文章的目的是阐述了线粒体DNA稳态在神经退行性疾病发病机制中的关键作用。线粒体DNA分布于核仁内,随后在线粒体颗粒区转录为多顺反子线粒体RNA分子。在线粒体核区和颗粒的超微结构中,与线粒体DNA复制、转录、线粒体DNA翻译、线粒体DNA监测和降解相关的关键线粒体蛋白参与线粒体结构、基因组及线粒体DNA加工过程。单亲遗传的线粒体DNA会发生可遗传的多倍体变异,包括同质性变异和异质性变异。线粒体DNA的累积变异,包括缺失、点突变和甲基化,在神经退行性疾病的致病过程中发生。线粒体DNA变异的增加可通过神经退行性疾病中有害异质性的增加传播,最终导致氧化磷酸化缺陷、生物发生缺陷和细胞代谢功能障碍。因此,开发适当的基因编辑工具以纠正异常的线粒体DNA变异,并针对与维持线粒体DNA稳态相关的关键蛋白质,可被视为治疗神经退行性疾病的潜在治疗策略。尽管针对线粒体DNA的治疗策略在疾病中展现出巨大潜力,但其疗效和安全性挑战需要对线粒体DNA在衰老和神经退行性疾病中的改变机制有更深入的了解。


https://orcid.org/0009-0001-3229-4360 (Wandi Xiong); 

http://orcid.org/0000-0003-2462-7935 (Ling Huang)

关键词: 衰老, 阿尔茨海默病, 异质性, 线粒体基因组, 线粒体DNA, 线粒体稳态, mtDNA突变, 线粒体单倍群, 神经退行性疾病, 帕金森病

Abstract: The mitochondrial genomic homeostasis is essential for the function of the oxidative phosphorylation system and cellular homeostasis. Mitochondrial DNA is particularly susceptible to aging-related oxidative stress due to the lack of a histone coat. Disturbances in mitochondrial DNA may contribute to functional decline during the aging process and in neurodegenerative diseases, leading to further impairment of mitochondrial DNA and initiating a vicious cycle. To date, it remains unclear how disturbed mitochondrial DNA is involved in the etiology of pathological aging and neurodegenerative diseases. The purpose of this review is to clarify the crucial roles of mitochondrial DNA homeostasis in the pathogenesis of neurodegenerative diseases. Mitochondrial DNA is distributed within nucleoids and is then transcribed into polycistronic mitochondrial DNA molecules within the mitochondrial granule region. Within the ultrastructure of the mitochondrial nucleoid and granule, a group of essential mitochondrial proteins involved in DNA replication, DNA transcription, RNA translation, RNA surveillance, and RNA degradation plays a crucial role in maintaining mitochondrial structure, genome integrity, and mitochondrial DNA processing. The uniparentally inherited mitochondrial DNA undergoes heritable polyploid variations, which include homoplasmy and heteroplasmy. Accumulating mitochondrial DNA alterations, such as deletions, point mutations, and methylations, occur during the pathogenic processes of neurodegenerative diseases. The increased mitochondrial DNA alterations can be propagated by the rise of deleterious heteroplasmy in neurodegenerative diseases, ultimately resulting in impairment to the oxidative phosphorylation system, biogenesis defects, and cellular metabolic dysfunction. Therefore, developing appropriate gene editing tools to rectify aberrant alterations in mitochondrial DNA and targeting the key proteins involved in maintaining mitochondrial DNA homeostasis can be considered promising therapeutic strategies for neurodegenerative diseases. Although therapeutic strategies targeting mitochondrial DNA in diseases show great potential, challenges related to efficacy and safety require a better understanding of the mechanisms underlying mitochondrial DNA alterations in aging and neurodegenerative diseases. 

Key words: aging, Alzheimer’s disease, heteroplamy, mitochondrial DNA mutation, mitochondrial DNA, mitochondrial genome, mitochondrial haplogroup, mitochondrial homeostasis, neurodegenerative diseases, Parkinson’s disease